Best Immunotherapy Companies in Boston, United States
The 39 best Immunotherapy companies in Boston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Fog Pharmaceuticals.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Boston
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Fog Pharmaceuticals Developer of cell-penetrating mini-proteins to target intracellular disease drivers | $531M | 30 mo ago | 97 97 → 197 (+103%) | — | Series E | — | — |
| 2 | Ziopharm Oncology Develops immunotherapies for the treatment of cancer and autoimmune diseases | $377M | 83 mo ago | 36 | Kevin Boyle CEO | Public | 160 patents Isophosphoramide mustard-based anti‑tumor agents for glioblastoma | — |
| 3 | Pyxis Oncology Developer of antibody therapeutics for treating cancer | $194M | 30 mo ago | 50 50 → 68 (+36%) | Thomas Gajewski Co-Founder | Public | 10 patents Targeted antibody‑drug conjugates against KLRC1, GPNMB, and fibronectin‑EDB for oncology. | — |
| 4 | TScan Therapeutics Developer of T cell therapies to harness the immune system against cancer | $180M | 67 mo ago | 154 154 → 151 (-2%) | — | Public | 162 patents TCR-mimic binding proteins for targeted cancer immunotherapy against tumor antigens | — |
| 5 | HilleVax Developer of a vaccine for norovirus infection | $135M | 60 mo ago | 62 | — | Public | — | — |
| 6 | Hillstar Bio Developer of precision immunotherapies for autoimmune diseases | $67M | 17 mo ago | — | Robert Mabry CEO | Series A | — | — |
| 7 | Normunity Developer of immunotherapies for the treatment of cancer | $65M | 19 mo ago | 19 | Lieping Chen Co-Founder | Series B | 4 patents Therapeutic monoclonal antibodies targeting KLK6, LY6K, and PLA2G10 proteins | — |
| 8 | Incendia Therapeutics Developer of immunotherapy for cancer treatment | $65M | 58 mo ago | 21 | Guy Clifton Co-Founder | Series A | — | — |
| 9 | Maverick Therapeutics Developer of T-cell-based antibody therapies for the treatment of cancer | $56M | 116 mo ago | 32 | — | Acquired | — | — |
| 10 | Kelonia Developer of medicines to treat autoimmune and inflammatory conditions | $50M | 52 mo ago | 45 | — | Acquired | — | — |
| 11 | Ankyra Developer of immunotherapies for the treatment of cancer | $45M | 57 mo ago | 10 | Darrell Irvine Co-Founder | Series B | — | — |
| 12 | Abpro Developer of antibody therapies for cancer and infectious diseases | $42M | 53 mo ago | 24 24 → 36 (+50%) | Ian Chan Co-Founder & CEO | Public | 28 patents Multispecific therapeutic antibodies for cancer and eye disease targets (HER2, CD3, VEGF/ANG2, Claudin‑18.2). | — |
| 13 | Monopteros Therapeutics Developer of immunotherapies for cancer treatment | $20M | 64 mo ago | — | Peter Keller CEO | Deadpooled | — | — |
| 14 | CoStim Pharmaceuticals Urban regeneration development company creating sustainable value through innovative real estate projects | $10M | 160 mo ago | 90 | — | Acquired | — | — |
| 15 | CureLab Developer of immunostimulants and vaccines against cancer | $7M | 223 mo ago | 10 | — | Funding Raised | 8 patents Engineered nucleic‑acid mutations for structured RNA/DNA design and vaccine development | — |
| 16 | Xios Therapeutics Immune-targeted small molecule therapies for cancer | $7M | 98 mo ago | 1 | Diala Ezzeddine President & CEO | Deadpooled | — | — |
| 17 | Symbiotix Biotherapies US-based, early-stage biopharma developing microbiome-derived zwitterionic polysaccharide-based therapeutics… | $5M | 106 mo ago | — | Dennis Kasper Co-Founder | Deadpooled | — | — |
| 18 | Adecto Pharmaceuticals Developing targeted cancer therapies and companion diagnostics for ADAM8-positive tumors | $4M | 48 mo ago | 3 | Gail Sonenshein Founder & President | Funding Raised | — | — |
| 19 | LAPIX Developer of immunotherapies for immunological diseases | $3M | 13 mo ago | 9 | Anas Fathallah Co-Founder & CEO | Series A | — | — |
| 20 | AbFero Pharmaceuticals Developer of oral iron chelators for the treatment of iron overload diseases | $2M | 65 mo ago | 3 | Raymond Bergeron Co-Founder & CSO | Seed | — | — |
| 21 | SIWA Therapeutics Developing a monoclonal antibody that targets and destroys senescent cells. | $2M | 111 mo ago | 9 | Misty Gruber Co-Founder & President | Seed | — | — |
| 22 | NanoTomer Developer of antibody and protein-based drug conjugates to treat cancer | $950K | 87 mo ago | 6 | Keith Greenfield Founder | Seed | 4 patents Engineered clathrin-mimetic chimeric antigen receptors for immune cell activation therapy | — |
| 23 | VaxSyna Developer of vaccine and antibody therapeutics | $437K | 53 mo ago | 4 | Joseph Hunter Co-Chief Executive Officer | Funding Raised | — | — |
| 24 | Oncolinx Developer of antibody-drug conjugates (ADCs) for cancer treatment | $350K | 118 mo ago | 2 | Riley Ennis Co-Founder & COO | Seed | — | — |
| 25 | Promakhos Therapeutics Developer of immunotherapies for the treatment of inflammatory diseases | $125K | 36 mo ago | 3 | Jasper Neggers Co-Founder | Seed | — | — |
| 26 | Guardian Bio Developer of cell-therapeutics for the treatment of cancer | $125K | 50 mo ago | 3 | Richard Barrett Co-Founder and CSO | Seed | — | — |
Top 12 Immunotherapy companies in Boston
#1
Series A · Boston, Massachusetts · founded 2023$67Mraised▾
Developer of precision immunotherapies for autoimmune diseases. It selectively targets and depletes pathogenic immune cells, leaving healthy cells unharmed. This targeted approach aims to provide durable relief through an immune reset, unlike traditional broad immunosuppression therapies. The company's pipeline includes therapies targeting specific immune-cell subsets, offering the potential for disease remission rather than just symptom management. Development leverages antibody engineering expertise and validated modalities, focusing on identifying patient populations most likely to benefit.
- Mar 2025Series A$67M
- Aug 2023Seed—
#2
Series B · Boston, Massachusetts · founded 2020 · 19 employees$65Mraised▾
Developer of immunotherapies for the treatment of cancer. It is developing a pipeline of immune normalizers to restore the immune system’s intrinsic activity to identify and eliminate cancer cells. The lead program is a monoclonal antibody targeting a secreted enzyme that is highly upregulated in multiple human cancers and drives the exclusion of T-cell infiltration in immuno-sensitive tumors.
- Jan 2025Series B$75M
- Oct 2022Series A$65M
#3
Series A · Boston, Massachusetts · founded 2019 · 9 employees$3.5Mraised▾
Developer of immunotherapies for immunological diseases. It offers a lead candidate LPX-TI641 for multiple sclerosis, Neuromyelitis Optica, Rheumatology, LPX-TIIBD for Inflammatory bowel disease, and also provides gene therapy.
- Jul 2025Series A$2.2M
- Aug 2024Series A$5.5M
- Oct 2022Seed$1.2M
#4
Series E · Boston, Massachusetts · founded 2015 · 97 employees$530.9Mraised▾
Fog Pharmaceuticals is developing cell-penetrating mini-proteins, molecules that combine the ability of proteins to target large flat surfaces, with the ability of small molecules to penetrate cells.
- Mar 2024Series E$145M
- Nov 2022Series D$178M
- Mar 2021Series C$107M
- Jan 2021Series B$23.3M
#5
Public · Boston, Massachusetts · founded 2019 · 50 employees$194.5Mraised▾
Developer of antibody therapeutics for treating cancer. The product pipeline includes PYX-201 that targets fibronectin, PYX-202 that targets tumor antigen, and PYX-203 for hematological cancer. The antibody is used for initiating the immune response in dysfunctional immune cells in the tumor microenvironment to treat cancer such as tumor antigen-specific tumor-infiltrating lymphocytes (TILs).
- Feb 2024Post IPO—
- Mar 2021Series B$172.5M
- Jul 2019Series A$22M
#6
Public · Boston, Massachusetts · founded 2003 · 36 employees$376.6Mraised▾
Ziopharm Oncology employing novel gene expression, control, and cell technologies to deliver safe, effective, and scalable cell-based therapies for the treatment of cancer and graft-versus-host-disease (GvHD), a type of auto-immune disease. The Company's synthetic immuno-oncology programs include chimeric antigen receptor-modified T cells (CAR-T), T-cell receptor (TCR)-modified T cells. The Company's preclinical and clinical pipeline focuses on the treatment of hematological and solid tumor malignancies (brain cancer), as well as GvHD, using cellular therapeutics.
- Sep 2019Post IPO$19.5M
- Jul 2019Post IPO$45M
- Nov 2018Post IPO$50M
- Jul 2016Post IPO$120M
#7
Public · Boston, Massachusetts · founded 1995 · 154 employees$180Mraised▾
Developer of T cell therapies to harness the immune system against cancer. The company focuses on hematologic malignancies and solid tumors using proprietary platforms like TargetScan and ReceptorScan. The company's product line include TSC-100 and TSC-101 target residual disease in AML, MDS, and ALL patients post-allogeneic hematopoietic cell transplant.
- Jan 2021Series C$100M
- Jan 2020Series B$35M
- Jul 2019Series B$23.3M
#8
Public · Boston, Massachusetts · founded 2021 · 62 employees$135Mraised▾
Developer of a vaccine for norovirus infection. The lead candidate HIL-214 is a norovirus bivalent GI.1/GII.4 virus-like particle vaccine indicated for active immunization for the prevention of acute gastroenteritis caused by norovirus.
- Sep 2021Series D$135M
#9
Public · Boston, Massachusetts · founded 2007 · 24 employees$42.4Mraised▾
Developer of antibody therapies for cancer and infectious diseases. It is developing a pipeline of differentiated tetravalent bispecific T-cell (TetraBi) antibodies for immuno-oncology. The lead candidate, ABP-100 is indicated for breast, gastric endometrial cancer, ABP-300 for covid-19, ABP-110 for liver cancer, ABP-150 for gastric cancer, and others.
- Apr 2022Series B$2M
- Jan 2020Series B$18M
- Apr 2017Series A$10M
- Mar 2016Series A$12.4M
#10
Acquired · Boston, Massachusetts · founded 2021 · 45 employees$50.3Mraised▾
Developer of medicines to treat autoimmune and inflammatory conditions. The company is developing a portfolio of therapeutic indications for tibulizumab, crebankitug, and torudokimab, with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders.
- Apr 2022Series A$50.3M
#11
Series A · Boston, Massachusetts · founded 2019 · 21 employees$65Mraised▾
Developer of immunotherapy for cancer treatment. It offers PRTH-101which is a monoclonal antibody that binds to and inhibits Discoidin Domain Receptor 1 that stimulate immune-based antitumor activity for advanced or metastatic solid tumors.
- Nov 2021Series A$65M
#12
Series B · Boston, Massachusetts · founded 2019 · 10 employees$45Mraised▾
Developer of immunotherapies for the treatment of cancer. The company is developing cancer therapies based on localized cytokines that activate a comprehensive anti-tumor immune response.
- Nov 2021Series B$45M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology in Boston is moving
A read on the academic research around Immunology in Boston — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 207 papers.
- Boston Children\'s Hospital90
- Boston University63
- Boston Children\'s Museum24
- Boston Medical Center24
- Dana-Farber/Boston Children\'s Cancer and Blood Disorders Center13
- Immune system2→22
- Immunotherapy2→10
- Cancer research2→5
- Melanoma1→3
- Cancer1→3
- Immune system4→45
- Immunotherapy2→37
- Antigen1→12
- Tumor microenvironment1→11
- Cytotoxic T cell1→7
- Immunotherapy12
- Immune system11
- Chimeric antigen receptor8
- Clinical trial6
- Disease3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.